To evaluate the role of trimethoprim/sulfamethoxazole (TMP/SMX) as an alternative to vancomycin for the treatment of severe Staphylococcus aureus infections.
DATA SOURCES
Clinical literature was accessed through MEDLINE (1966–February 2003) and EMBASE (1980–February 2003). Key search terms included trimethoprim/sulfamethoxazole combination and Staphylococcus aureus.
DATA SYNTHESIS
An evaluation of case reports, case series, and clinical studies focusing on the use of TMP/SMX for treatment of severe S. aureus infections was conducted. The majority of the reports indicate that TMP/SMX may be effective for the treatment of infections due to low bacterial burdens of susceptible strains of S. aureus.
CONCLUSIONS
In select infections, TMP/SMX may be a useful alternative to vancomycin for treatment of severe S. aureus infections. Additional randomized studies should be conducted comparing this agent with vancomycin and linezolid.
. BarrettFFMcGeheeRFFinlandM.Methicillin-resistant Staphylococcus aureus at Boston City Hospital. Bacteriologic and epidemiologic observations. N Engl J Med1968;279:441–8.
2.
. CDC NNIS System.National nosocomial infections surveillance (NNIS) system report, data summary January 1992–April 2001, issued August 2001. Am J Infect Control2001;29:400–21.
3.
. ChambersHF.The changing epidemiology of Staphylococcus aureus?Emerg Infect Dis2001;7:178–82.
4.
. FridkinSKEdwardsJRPichetteSCPryorERMcGowanJEJrTen-overFCDeterminants of vancomycin use in adult intensive care units in 41 United States hospitals. Clin Infect Dis1999;28:1119–25.
. Recommendations for preventing the spread of vancomycin resistance recommendations of the Hospital Infectious Control Practices Advisory Committee. MMWR Morb Mortal Wkly Rep1995;44(RR12):1–13.
7.
. MalbrunyBCanuABozdoganBFantinBZarroukVDutka-MalenSResistance to quinupristin/dalfopristin due to mutation of L22 ribo-somal protein in Staphylococcus aureus. Antimicrob Agents Chemother2002;46:2200–7.
8.
. TsiodrasSGoldHSSakoulasGEliopoulosGMWennerstenCVenkataramanLLinezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet2001;358:207–8.
. LevineDOFromnBSReddyBR.Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med1991;109:619–24.
11.
. Centers for Disease Control and Prevention.Public health dispatch: vancomycin-resistant Staphylococcus aureus—Pennsylvania. MMWR Morb Mortal Wkly Rep2002;51:902.
12.
. Centers for Disease Control and Prevention.Staphylococcus aureus resistant to vancomycin—United States. MMWR Morb Mortal Wkly Rep2002;51:565–7.
13.
. CloseSJMcBurneyCRGarvinCGChenDCMartinSJ.Trimethoprim–sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate Staphylococcus aureus. Pharmacotherapy2002;22:983–9.
14.
. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY antimicrobial surveillance program, 1997–1999. Clin Infect Dis2001;32(suppl 2):S114–32.
15.
. YeldaniCStrodtmanRLentinoR.In vitro and in vivo studies of trimethoprim–sulfamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother1988;22:873–80.
16.
. HuovinenP.Resistance to trimethoprim–sulfamethoxazole. Clin Infect Dis2001;32:1608–14.
17.
. ShafqatSHShahSAASyedSA.Bacterial endocarditis over prosthetic valves treated with trimethoprim–sulphamethoxazole combination. Br Heart J1971;33:974–6.
18.
. TamerMABrayJD.Trimethoprim–sulfamethoxazole treatment of multi–antibiotic-resistant staphylococcus endocarditis and meningitis. Clin Pediatr1982;21:125–6.
19.
. BajpaiJChaturvediSNKhanujaSPS.Chemotherapy of acute bone and joint infections. Int Surg1977;62:172–4.
20.
. JemniLHmoudaHLetaiefA.Efficacy of trimethoprim–sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus: a report from Tunisia. Clin Infect Dis1994;19:202–3.
21.
. SeligmanSJMadhavanTAlcidD.Trimethoprim–sulfamethoxazole in the treatment of bacterial endocarditis. J Infect Dis1973;128(suppl):S754–61.
22.
. RuizMEGuerreroICTuazonCU.Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis2002;35:1018–20.
23.
. MarkowitzNQuinnELSaravolatzLD.Trimethoprim–sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med1992;117:380–98.
24.
. SteinABatailleJFDrancourtMCurvaleGArgensonJNGroulierPAmbulatory treatment of multi-drug resistant Staphylococcus-infected orthopedic implants with high-dose oral cotrimoxazole (trimethoprim–sulfamethoxazole). Antimicrob Agents Chemother1998;42:3086–91.
25.
. De GorgolasMAvilesPVerdejoCGuerrerMLF.Treatment of experimental endocarditis due to methicillin-susceptible and methicillin-resistant Staphylococcus aureus with trimethoprim–sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother1995;39:953–7.
